We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

ANKYLOSING SPONDYLITIS MARKET ANALYSIS

Ankylosing Spondylitis Market, by Drug Type (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Disease-modifying Anti-rheumatic Drugs (DMARDs), TNF Inhibitors, Corticosteroids, and Others), by Route of Administration (Oral and Parentral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 20201- 2028

  • Published In : Dec 2021
  • Code : CMI4833
  • Pages :190
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Ankylosing Spondylitis MarketSize and Trends

The global ankylosing spondylitis market is estimated to be valued at US$ 4,864.3 million in 2021 and is expected to exhibit a CAGR of 8.2% during the forecast period (2021-2028).

Figure 1.Global Ankylosing Spondylitis Market Share (%) in Terms of Value, by Drug Type, 2021

Increasing prevalence of ankylosing spondylitis is expected to drive the market growth during the forecast period.

The increasing prevalence of ankylosing spondylitis is expected to drive the global ankylosis spondylitis market growth during the forecast period. For instance, according to an article published by ‘Frontiers in Medicine’ journal in March 2021, the epidemiological data in Taiwan stated that the prevalence of ankylosing spondylitis is 96.9 per 100,000 people.

Figure 2. Global Ankylosing Spondylitis Market Share (%), by Distribution Channel, 2021

Increasing strategic alliances between the companies to develop or to expand the availability of drugs is expected to drive the market growth during the forecast period.

Key players in the market are focusing on inorganic growth strategies, such as partnerships and collaborations which is expected to drive the market growth during the forecast period.

For instance, in August 2021, Inmagene Biopharmaceuticals, a leading biotech company focused on the development of therapeutics for immunology-related diseases, and Affibody AB, a company developing innovative bi- and multi-specific next-generation biopharmaceuticals, working in a partnership, announced the successful dosing of the first patient in the global ASPIRE phase 2 trial evaluating izokibep (IMG-020 or ABY-035) for treating ankylosing spondylitis (AS).

Global Ankylosing Spondylitis Market – Impact of Coronavirus (COVID-19) Pandemic

Accessing medical services can be challenging for people with ankylosing spondylitis during the COVID-19 pandemic. While some drugs for ankylosing spondylitis can be self-administered, some are given through an IV in hospitals. Similarly, physical therapy requires a visit to the physical therapist, which has been difficult due to the COVID-19 pandemic.

Biologics such as TNF (Tumor Necrosis factor) inhibitors, used in ankylosing spondylitis treatment, may increase the risk of infections and lower the body's ability to fight infections, including COVID-19, because these medications cause a suppressing effect on the immune system. Biologics including IL-17 and IL-12/23 inhibitors are used for treating ankylosing spondylitis, but have the same immunosuppressive effect that may increase the risk of infections. Thus, due to this, the growth of the global ankylosing spondylitis market is expected to be hampered.

Ankylosing spondylitis is an immune-mediated inflammatory disease (IMID). According to a study conducted in Ontario, Canada, in 2020, it was found that people with IMIDs were tested for COVID-19 at a 20% higher rate, as compared to the general population.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.